← Back to Search

Unknown

VX-548 for Pain

Phase 1
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 up to day 44
Awards & highlights

Study Summary

This trial tests how a drug affects people's bodies and if it is safe and tolerable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 up to day 44
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 up to day 44 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-548 and its Metabolite
Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-548 and its Metabolite
Maximum Observed Plasma Concentration (Cmax) of VX-548 and its Metabolite
Secondary outcome measures
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: VX-548Experimental Treatment1 Intervention
Participants will be randomized to receive a single dose of VX-548 in 1 of 6 treatment sequences with 3 dosing periods to assess different fed conditions and timing of meal administration on the PK of VX 548. There will be a 14 day washout period between each dosing period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-548
2022
Completed Phase 3
~3540

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
246 Previous Clinical Trials
32,509 Total Patients Enrolled
17 Trials studying Pain
1,209 Patients Enrolled for Pain

Media Library

VX-548 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05851157 — Phase 1
Pain Research Study Groups: VX-548
Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05851157 — Phase 1
VX-548 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05851157 — Phase 1
~35 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top